[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100546024":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":8,"centralContacts":13,"locations":23,"responsibleParty":39,"collaborators":7,"id":41,"slug":7,"hasResults":42,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":7,"eligibilityCriteria":46,"healthyVolunteers":42,"sex":47,"minAge":48,"maxAge":7,"enrollmentInfo":49,"targetDuration":7,"studyType":52,"phases":7,"briefSummary":53,"conditions":54,"keywords":7,"overallStatus":26,"whyStopped":7,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":65},{"fullName":5,"class":6},"HK inno.N Corporation","INDUSTRY",null,[9],{"name":10,"affiliation":11,"role":12},"Myung-Ah Lee","Seoul St. Mary's Hospital","STUDY_CHAIR",[14,19],{"name":15,"role":16,"phone":17,"phoneExt":7,"email":18},"Soyeon Ahn","CONTACT","82-2-6477-0252","soyeon.ahn@inno-n.com",{"name":20,"role":16,"phone":21,"phoneExt":7,"email":22},"Yongan Jeong","82-2-6477-0255","yongan.jeong@inno-n.com",[24],{"facility":25,"status":26,"city":27,"state":7,"zip":7,"country":28,"cosmosGeoPoint":29,"geoPoint":34,"contacts":35},"Seoul ST. Mary's Hospital","RECRUITING","Seoul","South Korea",{"type":30,"coordinates":31},"Point",[32,33],126.9784,37.566,{"lat":33,"lon":32},[36,37],{"name":10,"role":16,"phone":7,"phoneExt":7,"email":7},{"name":10,"role":38,"phone":7,"phoneExt":7,"email":7},"PRINCIPAL_INVESTIGATOR",{"type":40,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100546024",false,"NCT06389552","Long-term Observational Study to Evaluate the DFS and OS of Adjuvant FOLFIRINOX Regimen in Pancreatic Cancer Patients","A Long-term Follow-up Study of FOLFIRINOX Regimen as Adjuvant Therapy in Pancreatic Cancer Patients After Curative Surgery: Multi-center, Prospective","Inclusion Criteria:\n\n* Age over 19 at the time of obtaining the informed consent form\n* Planning to FOLFIRINOX as adjuvant therapy after pancreatic cancer surgery\n* ECOG 0 or 1\n* Scheduled to RO or R1 resection\n* Organ function capable of chemotherapy\n\nExclusion Criteria:\n\n* FOLFIRINOX contraindications among the drug approval requirements\n* Palliative Therapy\n* Experienced toxic reactions or Hypersensitivity reactions of FOLFIRINOX","ALL","19 Years",{"count":50,"type":51},36,"ESTIMATED","OBSERVATIONAL","This study is designed to evaluate the safety and efficacy of adjuvant FOLFIRINOX regimen in pancreatic cancer patients after curative surgery.",[55],"Adjuvant Chemotherapy","2024-04-24",{"date":58,"type":59},"2024-04-29","ACTUAL",{"date":61,"type":59},"2023-09-25",{"date":63,"type":51},"2027-12",{"name":5,"class":6},1]